Loading...

VRDN VIRIDIAN THERAPEUTICS INC Product Launches 8-K Filing

VRDN

VRDN

VIRIDIAN THERAPEUTICS INC

(VRDN)

2024 8-K

Show Summary

Summary

Financial Statements

Director Appointment

Stock Sale Agreement

Financial Results

CFO Appointment

Positive Trial Results

Financial Results

Positive Trial Results

Financial Results

Investor Presentation

Annual Meeting Approval

Financial Results

Lease Agreement Amendment

Financial Results

Underwriting Agreement

Departure and Appointment o...

Financial Results

Resignation and Bylaws Adop...

Private Placement and Manag...

Appointment of Director

Management Change

Regulation FD Disclosure

Annual Meeting Approval

Financial Results

Departure of Directors

Regulation FD Disclosure

Financial Results

Appointment of President an...

External Links:

Viridian Therapeutics announced positive topline results from its phase 3 THRIVE trial of VRDN-001 for thyroid eye disease, showing significant improvements in symptoms and a favorable safety profile, with plans for further trials and a BLA submission in 2025.

AI Assistant

VIRIDIAN THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.